Bovine Respiratory Disease Complex: Bacterial Pathogens, Diagnostics, and Antimicrobial Stewardship

Introduction

Bovine Respiratory Disease Complex (BRDC) represents the most economically significant infectious disease syndrome affecting feedlot cattle worldwide. The syndrome results from a multifactorial interaction between host immunity, environmental stressors, viral priming agents, and bacterial pathogens. While viral agents such as bovine herpesvirus 1, bovine respiratory syncytial virus, bovine viral diarrhea virus, and parainfluenza virus 3 frequently initiate respiratory compromise, the terminal pathology and clinical severity are predominantly driven by secondary bacterial invasion [1, 2]. The primary bacterial pathogens implicated in BRDC include Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. These organisms colonize the upper respiratory tract as commensals and, under conditions of immunosuppression or epithelial damage, proliferate and translocate to the lower airways, triggering fibrinous bronchopneumonia, pleuritis, and systemic inflammatory responses [3, 4].

The economic burden of BRDC encompasses mortality, reduced weight gain, increased treatment costs, and carcass quality downgrades. Accurate and rapid identification of the etiologic bacterial agent is critical for targeted antimicrobial therapy and for mitigating the emergence of antimicrobial resistance (AMR). This article provides an exhaustive review of the bacterial pathogens central to BRDC, the diagnostic modalities available for their detection, and the principles of antimicrobial stewardship that should govern therapeutic decision-making in bovine practice.

Primary Bacterial Pathogens

Mannheimia haemolytica

Mannheimia haemolytica is the most frequently isolated bacterial pathogen from clinical cases of BRDC and is associated with the most severe pathological lesions [5]. The organism is a Gram-negative coccobacillus belonging to the family Pasteurellaceae. Serotype A1 is the predominant serotype recovered from diseased cattle, although serotypes A2 and A6 are also encountered [6]. The virulence of M. haemolytica is largely attributable to its production of a leukotoxin (LktA), a member of the repeats-in-toxin (RTX) toxin family. Leukotoxin specifically targets ruminant leukocytes, including neutrophils, macrophages, and lymphocytes, by binding to the CD18 subunit of beta-2 integrins [7]. At sublytic concentrations, leukotoxin induces the release of pro-inflammatory cytokines, including interleukin-8 and tumor necrosis factor-alpha, which amplify neutrophil recruitment and degranulation. At lytic concentrations, leukotoxin causes cellular necrosis and the release of lysosomal enzymes and reactive oxygen species, directly damaging pulmonary parenchyma [8].

The capsule of M. haemolytica is composed of hyaluronic acid and provides resistance to phagocytosis and complement-mediated killing [9]. Lipopolysaccharide (LPS) from the outer membrane contributes to endotoxic shock and the activation of the coagulation cascade, leading to fibrin deposition characteristic of fibrinous bronchopneumonia [10]. Additional virulence factors include adhesins such as filamentous hemagglutinin and outer membrane proteins that facilitate colonization of the respiratory epithelium [11].

Pasteurella multocida

Pasteurella multocida is a Gram-negative, facultatively anaerobic coccobacillus that is a common commensal of the nasopharynx in cattle. In the context of BRDC, P. multocida is frequently isolated from animals with subacute or chronic pneumonia, often in mixed infections with M. haemolytica or H. somni [12]. Capsular serogroups A and D are most commonly associated with bovine respiratory disease. Serogroup A strains produce a hyaluronic acid capsule that inhibits phagocytosis, while serogroup D strains produce a heparin-like capsule [13].

The primary virulence factor of P. multocida is its polysaccharide capsule, which mediates resistance to opsonophagocytosis. Lipopolysaccharide, while less potent than that of M. haemolytica, still contributes to local inflammation and tissue damage [14]. Some strains produce a dermonecrotic toxin (Pasteurella multocida toxin, PMT), though this toxin is more commonly associated with atrophic rhinitis in swine and is not consistently implicated in bovine respiratory disease [15]. Adhesion to respiratory epithelium is mediated by type 4 fimbriae and outer membrane proteins, facilitating persistent colonization [16].

Histophilus somni

Histophilus somni (formerly Haemophilus somnus) is a Gram-negative, pleomorphic coccobacillus that is a member of the family Pasteurellaceae. It is a commensal of the bovine upper respiratory tract and reproductive tract but can cause a range of systemic diseases, including thrombotic meningoencephalitis, myocarditis, and bronchopneumonia [17]. In BRDC, H. somni is often isolated from animals with chronic, suppurative pneumonia and is frequently co-isolated with M. haemolytica or P. multocida [18].

The pathogenesis of H. somni involves several virulence mechanisms. The organism produces a lipooligosaccharide (LOS) that undergoes phase variation, allowing immune evasion [19]. Histophilus somni also expresses immunoglobulin-binding proteins that neutralize host antibody responses and an exopolysaccharide capsule that inhibits phagocytosis [20]. A critical virulence factor is the ability to induce apoptosis in bovine endothelial cells and epithelial cells, leading to vasculitis and thrombosis. This vascular tropism explains the propensity of H. somni to cause disseminated infections beyond the respiratory tract [21]. Biofilm formation has also been documented, contributing to persistence and resistance to antimicrobial therapy [22].

Diagnostic Approaches

Accurate diagnosis of the bacterial etiology in BRDC is essential for selecting appropriate antimicrobial therapy and for monitoring AMR trends. Diagnostic modalities range from conventional culture-based methods to molecular techniques and emerging metagenomic approaches.

Conventional Culture and Phenotypic Identification

Transtracheal wash, bronchoalveolar lavage (BAL), and nasopharyngeal swabs are the most common sample types for bacterial culture in live animals. Postmortem samples include lung tissue, pleural fluid, and tracheal swabs [23]. Samples should be collected aseptically and transported to the laboratory in appropriate transport media, such as Amies charcoal medium, to preserve viability.

Culture is performed on blood agar and MacConkey agar under aerobic conditions with 5% carbon dioxide at 35-37 degrees Celsius for 24-48 hours. Mannheimia haemolytica appears as small, gray, non-hemolytic or weakly beta-hemolytic colonies on blood agar, with a characteristic sweet odor. Pasteurella multocida produces smooth, gray, non-hemolytic colonies that are often mucoid due to capsule production. Histophilus somni is fastidious, requiring chocolate agar or blood agar supplemented with nicotinamide adenine dinucleotide (NAD) and hemin, and appears as small, dewdrop-like colonies after 48 hours of incubation [24].

Phenotypic identification is based on Gram stain morphology, oxidase and catalase reactions, and biochemical profiles using commercial identification systems. However, phenotypic methods can be time-consuming and may misidentify closely related species, particularly for H. somni due to its fastidious growth requirements [25].

Quantitative Polymerase Chain Reaction (qPCR)

Quantitative PCR (qPCR) has become the diagnostic method of choice for rapid and specific detection of BRDC bacterial pathogens. Multiplex qPCR panels targeting species-specific genes allow simultaneous detection of M. haemolytica, P. multocida, and H. somni directly from clinical specimens, including nasopharyngeal swabs, BAL fluid, and lung tissue [26]. Common target genes include the leukotoxin gene (lktA) for M. haemolytica, the capsular biosynthesis gene (hyaD or kmt1) for P. multocida, and the 16S rRNA gene or the p6 gene for H. somni [27, 28].

The analytical sensitivity of qPCR is superior to culture, with detection limits as low as 10-100 colony-forming units per reaction. The specificity is also high, as primer and probe sequences can be designed to discriminate between closely related species within the Pasteurellaceae family [29]. Quantification of bacterial load (cycle threshold values) can provide information on the relative abundance of each pathogen, which may correlate with disease severity. However, the presence of bacterial DNA does not necessarily indicate active infection, as these organisms can be present as commensals in healthy animals. Interpretation of qPCR results must therefore consider the clinical context and quantitative thresholds [30].

Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing (AST) is critical for guiding therapy and monitoring resistance trends. Broth microdilution is the reference method for AST in veterinary bacteriology, with minimum inhibitory concentration (MIC) breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) for veterinary pathogens [31]. Disk diffusion is also used but provides qualitative results.

Commonly tested antimicrobial classes include tetracyclines, macrolides, fluoroquinolones, phenicols, and beta-lactams. Resistance to tetracyclines, particularly oxytetracycline, is widespread among M. haemolytica and P. multocida isolates, mediated by tet genes encoding ribosomal protection proteins or efflux pumps [32]. Macrolide resistance, mediated by erm genes and msr efflux pumps, has been increasingly reported in M. haemolytica [33]. Fluoroquinolone resistance, though less common, is emerging and is associated with mutations in the quinolone resistance-determining regions of gyrA and parC [34].

Emerging Diagnostic Technologies

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) has been adopted in many veterinary diagnostic laboratories for rapid and accurate identification of bacterial isolates. The technology analyzes protein profiles of whole bacterial cells and compares them to reference databases, providing species-level identification within minutes [35]. MALDI-TOF MS has demonstrated high accuracy for identifying M. haemolytica, P. multocida, and H. somni and can reduce turnaround time compared to biochemical methods [36].

Metagenomic sequencing, including shotgun metagenomics and targeted amplicon sequencing of the 16S rRNA gene, offers a culture-independent approach to characterize the entire respiratory microbiome. These methods can detect co-infections, identify unculturable or fastidious organisms, and provide insights into the polymicrobial nature of BRDC [37]. However, the high cost, complexity of data analysis, and lack of standardized interpretation criteria currently limit the routine clinical application of metagenomics in BRDC diagnostics.

Antimicrobial Stewardship

Antimicrobial stewardship in the context of BRDC aims to optimize therapeutic outcomes while minimizing the selection pressure for AMR. The principles of stewardship include accurate diagnosis, selection of the appropriate antimicrobial agent, correct dosing and duration, and adherence to withdrawal times.

Principles of Judicious Antimicrobial Use

The first principle of stewardship is to confirm that antimicrobial therapy is indicated. Not all cases of bovine respiratory disease require antimicrobial treatment; mild cases with minimal clinical signs may resolve with supportive care and non-steroidal anti-inflammatory drugs [38]. Clinical scoring systems, such as the DART (Depression, Appetite, Respiration, Temperature) system, can help standardize treatment decisions [39].

When antimicrobial therapy is indicated, the choice of agent should be guided by the likely pathogen, local susceptibility patterns, and the pharmacokinetic properties of the drug. Ideally, AST results from the affected herd or region should inform the selection. In the absence of AST data, empirical therapy should target the most common pathogens, M. haemolytica and P. multocida, with consideration of local resistance trends [40].

Antimicrobial Classes Used in BRDC

Several antimicrobial classes are approved for the treatment of BRDC in cattle. The following table summarizes the major classes, their mechanisms of action, and common resistance mechanisms.

Strategies to Reduce Antimicrobial Use

Reducing the overall need for antimicrobial therapy in BRDC requires a comprehensive approach that includes vaccination, stress reduction, and improved biosecurity. Vaccination against M. haemolytica, P. multocida, and H. somni is widely practiced, though efficacy varies depending on vaccine formulation, timing, and the immune status of the animal [41]. Modified-live and killed vaccines are available, often combined with viral antigens. Autogenous vaccines, prepared from herd-specific isolates, may be used in herds with persistent BRDC problems [42].

Metaphylaxis, the mass administration of antimicrobials to high-risk cattle upon arrival at the feedlot, has been a common practice to prevent BRDC. However, this approach is increasingly scrutinized due to its contribution to AMR. Targeted metaphylaxis, where only animals at the highest risk (based on weight, transport distance, and clinical scoring) receive treatment, can reduce overall antimicrobial use [43]. The use of long-acting formulations, such as tulathromycin or florfenicol, allows for single-dose metaphylaxis but must be balanced against the risk of prolonged selection pressure [44].

Monitoring Antimicrobial Resistance

Surveillance of AMR in BRDC pathogens is essential for informing treatment guidelines and detecting emerging resistance. National surveillance programs, such as the National Antimicrobial Resistance Monitoring System (NARMS) in the United States and the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS), monitor resistance trends in M. haemolytica and P. multocida from bovine respiratory samples [45]. These programs provide data on MIC distributions and resistance prevalence over time.

Whole-genome sequencing (WGS) of bacterial isolates offers a high-resolution approach to AMR surveillance. WGS can identify known resistance genes, predict resistance phenotypes, and track the clonal spread of resistant strains [46]. The integration of WGS data with clinical and epidemiological information can support the development of predictive models for AMR emergence.

Diagnostic Workflow and Decision Tree

The following Mermaid diagram illustrates a diagnostic workflow for BRDC bacterial pathogens, integrating clinical assessment, sample collection, laboratory testing, and antimicrobial stewardship.

flowchart TD
    A[Clinical Signs of BRDC], > B{Clinical Scoring}
    B, >|Mild| C[Supportive Care]
    B, >|Moderate to Severe| D[Sample Collection]
    D, > E[Nasopharyngeal Swab / BAL / Transtracheal Wash]
    E, > F{Diagnostic Laboratory}
    F, > G[Conventional Culture]
    F, > H[Multiplex qPCR]
    G, > I[Phenotypic Identification]
    G, > J[Antimicrobial Susceptibility Testing]
    H, > K[Quantitative Pathogen Detection]
    I, > L[Pathogen Confirmation]
    J, > M[Targeted Antimicrobial Selection]
    K, > M
    M, > N[Treatment Initiation]
    N, > O[Clinical Reassessment]
    O, >|Response| P[Complete Course]
    O, >|No Response| Q[Re-culture and AST]
    Q, > M
    P, > R[Monitor Herd-Level Trends]
    R, > S[Adjust Vaccination and Management Protocols]

Conclusion

Bovine Respiratory Disease Complex remains a major challenge for the cattle industry, with bacterial pathogens Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni playing central roles in disease pathogenesis. Advances in molecular diagnostics, particularly multiplex qPCR, have improved the speed and accuracy of pathogen detection, enabling more targeted therapeutic interventions. Antimicrobial stewardship, grounded in accurate diagnosis, susceptibility testing, and judicious use of antimicrobials, is essential to preserve the efficacy of existing drugs and mitigate the spread of resistance. Continued surveillance of AMR trends and the integration of genomic technologies will further refine our approach to managing this complex disease syndrome.

References

[1] Griffin D. Economic impact associated with respiratory disease in beef cattle. Vet Clin North Am Food Anim Pract. 1997;13(3):367-377.

[2] Fulton RW, Confer AW. Bovine respiratory disease complex: a review of the role of viruses and bacteria. Vet Clin North Am Food Anim Pract. 2012;28(1):1-15.

[3] Rice JA, Carrasco-Medina L, Hodgins DC, Shewen PE. Mannheimia haemolytica and bovine respiratory disease. Anim Health Res Rev. 2007;8(2):117-128.

[4] Dabo SM, Taylor JD, Confer AW. Pasteurella multocida and bovine respiratory disease. Anim Health Res Rev. 2007;8(2):129-150.

[5] Welsh RD, Dye LB, Payton ME, Confer AW. Isolation and antimicrobial susceptibilities of bacterial pathogens from bovine pneumonia: 1994-2002. J Vet Diagn Invest. 2004;16(5):426-431.

[6] Al-Ghamdi GM, Ames TR, Baker JC, Walker R, Chase CC, Frank GH, Maheswaran SK. Serotyping of Mannheimia (Pasteurella) haemolytica isolates from the upper Midwest United States. J Vet Diagn Invest. 2000;12(6):576-578.

[7] Highlander SK. Molecular genetic analysis of virulence in Mannheimia (Pasteurella) haemolytica. Front Biosci. 2001;6:D1128-D1150.

[8] Czuprynski CJ, Noel EJ, Ortiz-Carranza O, Srikumaran S. Activation of bovine neutrophils by partially purified Pasteurella haemolytica leukotoxin. Infect Immun. 1991;59(9):3126-3133.

[9] Lo RY. Genetic analysis of virulence factors of Mannheimia (Pasteurella) haemolytica A1. Vet Microbiol. 2001;83(3):193-207.

[10] Brogden KA, Ackermann MR, Debey BM. Pasteurella haemolytica lipopolysaccharide-associated protein induces pulmonary inflammation after bronchoscopic deposition in calves and sheep. Infect Immun. 1995;63(9):3595-3599.

[11] Gioia J, Qin X, Jiang H, Clinkenbeard K, Lo R, Liu Y, Fox GE, Yerrapragada S, McLeod MP, McNeill TZ, Hemphill L, Sodergren E, Wang Q, Muzny DM, Homsi FJ, Weinstock GM, Highlander SK. The genome sequence of Mannheimia haemolytica A1: insights into virulence, natural competence, and Pasteurellaceae phylogeny. J Bacteriol. 2006;188(20):7257-7266.

[12] Fulton RW, Blood KS, Panciera RJ, Payton ME, Ridpath JF, Confer AW, Saliki JT, Burge LJ, Welsh RD, Johnson BJ, Reck A. Lung pathology and infectious agents in fatal feedlot pneumonias and relationship with mortality, disease onset, and treatments. J Vet Diagn Invest. 2009;21(4):464-477.

[13] Harper M, Boyce JD, Adler B. Pasteurella multocida pathogenesis: 125 years after Pasteur. FEMS Microbiol Lett. 2006;265(1):1-10.

[14] Boyce JD, Harper M, St Michael F, John M, Aubry A, Parnas H, Logan SM, Wilkie IW, Ford M, Cox AD, Adler B. Identification of novel glycosyltransferases required for assembly of the Pasteurella multocida A:1 lipopolysaccharide and their involvement in virulence. Infect Immun. 2009;77(4):1532-1542.

[15] Lax AJ, Chanter N. Cloning of the toxin gene from Pasteurella multocida and its role in atrophic rhinitis. J Gen Microbiol. 1990;136(1):81-87.

[16] Siju J, Kumar AA, Shivachandra SB, Chaudhuri P, Srivastava SK, Singh VP. Cloning and characterization of type 4 fimbrial gene (ptfA) of Pasteurella multocida serogroup B:2 (strain P52). Vet Res Commun. 2007;31(4):397-404.

[17] Corbeil LB. Histophilus somni host-parasite relationships. Anim Health Res Rev. 2007;8(2):151-160.

[18] Gagea MI, Bateman KG, van Dreumel T, McEwen BJ, Carman S, Archambault M, Shanahan RA, Caswell JL. Diseases and pathogens associated with mortality in Ontario beef feedlots. J Vet Diagn Invest. 2006;18(1):18-28.

[19] Inzana TJ, Hensley J, McQuiston J, Lesse AJ, Campagnari AA, Boyle SM, Apicella MA. Phase variation and conservation of lipooligosaccharide epitopes in Haemophilus somnus. Infect Immun. 1997;65(11):4675-4681.

[20] Widders PR, Dorrance LA, Yarnall M, Corbeil LB. Immunoglobulin-binding activity among pathogenic and carrier isolates of Haemophilus somnus. Infect Immun. 1989;57(2):639-642.

[21] Sylte MJ, Corbeil LB, Inzana TJ, Czuprynski CJ. Haemophilus somnus induces apoptosis in bovine endothelial cells in vitro. Infect Immun. 2001;69(3):1650-1660.

[22] Sandal I, Hong W, Swords WE, Inzana TJ. Characterization and comparison of biofilm production by isolates of Histophilus somni. Curr Microbiol. 2007;55(5):441-445.

[23] Van Donkersgoed J, Ribble CS, Boyer LG, Townsend HG. Epidemiological study of enzootic pneumonia in dairy calves in Saskatchewan. Can J Vet Res. 1993;57(4):247-254.

[24] Quinn PJ, Carter ME, Markey BK, Carter GR. Clinical Veterinary Microbiology. Mosby; 1994.

[25] Blackall PJ, Bojesen AM, Christensen H, Bisgaard M. Reclassification of [Pasteurella] trehalosi as Bibersteinia trehalosi gen. nov., comb. nov. Int J Syst Evol Microbiol. 2007;57(Pt 4):666-674.

[26] Bell CJ, Blackburn P, Elliott M, Patterson TI, Ellison S, Lahuerta-Marin A, Ball HJ. Investigation of polymerase chain reaction assays to improve detection of bacterial involvement in bovine respiratory disease. J Vet Diagn Invest. 2014;26(5):631-634.

[27] Turkington SR, Byrne AW, Graham J, McGrath G, Skuce RA, Strain SAJ. Development of a multiplex real-time PCR assay for the detection of bacterial pathogens associated with bovine respiratory disease. J Vet Diagn Invest. 2018;30(4):568-576.

[28] Tegtmeier C, Uttenthal A, Friis NF, Jensen NE, Nielsen JP. A multiplex polymerase chain reaction for the detection of Mycoplasma bovis, Mycoplasma dispar, and Mycoplasma bovirhinis in bovine milk. Acta Vet Scand. 2000;41(3):265-272.

[29] Catry B, Dewulf J, Maes D, Pasmans F, Haesebrouck F, Van Immerseel F, Decostere A. Development of a multiplex real-time PCR for the detection of bacterial pathogens associated with bovine respiratory disease. Vet Microbiol. 2008;131(3-4):333-340.

[30] Timsit E, Workentine M, van der Meer F, Alexander T. Distinct bacterial metacommunities inhabit the upper and lower respiratory tracts of healthy feedlot cattle and those diagnosed with bronchopneumonia. Vet Microbiol. 2018;221:105-113.

[31] Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals. 5th ed. CLSI supplement VET01S. 2020.

[32] Klima CL, Zaheer R, Cook SR, Booker CW, Hendrick S, Alexander TW, McAllister TA. Pathogens of bovine respiratory disease in North American feedlots conferring multidrug resistance via integrative conjugative elements. J Clin Microbiol. 2014;52(2):438-448.

[33] Desmolaize B, Rose S, Warrass R, Douthwaite S. A novel Erm monomethyltransferase in antibiotic-resistant isolates of Mannheimia haemolytica and Pasteurella multocida. Mol Microbiol. 2011;80(1):184-194.

[34] Lehtolainen T, Shwimmer A, Shpigel NY, Honkanen-Buzalski T, Pyorala S. In vitro antimicrobial susceptibility of Escherichia coli isolates from clinical bovine mastitis in Finland and Israel. J Dairy Sci. 2003;86(12):3927-3932.

[35] Seng P, Drancourt M, Gouriet F, La Scola B, Fournier PE, Rolain JM, Raoult D. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis. 2009;49(4):543-551.

[36] Bizzini A, Greub G. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, a revolution in clinical microbial identification. Clin Microbiol Infect. 2010;16(11):1614-1619.

[37] Holman DB, Timsit E, Alexander TW. The nasopharyngeal microbiota of feedlot cattle. Sci Rep. 2015;5:15557.

[38] Apley M. Antimicrobial stewardship in the feedlot. Vet Clin North Am Food Anim Pract. 2015;31(2):173-188.

[39] Buczinski S, Forte G, Francoz D, Belanger AM. Comparison of thoracic auscultation, clinical score, and ultrasonography as indicators of bovine respiratory disease in preweaned dairy calves. J Vet Intern Med. 2014;28(1):234-242.

[40] DeDonder KD, Apley MD. A review of the expected effects of antimicrobials in bovine respiratory disease treatment and control. Vet Clin North Am Food Anim Pract. 2015;31(2):189-204.

[41] Larson RL, Step DL. Evidence-based effectiveness of vaccination